Layer, Chiang, et al. Genome Biology
Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.
REGN is expanding its genomics efforts and operations, building upon its strengths in mouse genetics (VelociGene®; VelocImmune® and related technologies) and genetics-driven drug discovery and development (e.g. Interleukin-1 blocker rilonacept, FDA approved in 2008; PCSK9 antibody alirocumab, in Phase 3; and several other important pipeline medicines). Specific activities being scaled up will include whole exome and whole genome sequencing projects, functional biology and mouse genetics for disease modeling, and translational research integrating genetics discovery research with REGN's growing pipeline development efforts. Along with others in industry and academia, Regeneron has long seen human genetics and genomics as essential platforms for facilitating and enabling drug discovery and development; we believe technological advances and other trends now make it possible to more fully realize this potential.
Goals for REGN's programs include target discovery, indication discovery, and patient-disease stratification through the use of human genetics and related genomic sciences. Regeneron’s interests encompass a breadth of different areas spanning Mendelian and family frameworks, large scale population genetics (both common and rare variants), and gene-gene interactions. The company will rely on its internal assets and technologies as well as continue to collaborate with investigators around the world in pursuing exciting genetics discovery projects. Regeneron is looking for talented and motivated individuals to join the company, complement internal teams and resources, and help lead these exciting programs and expanded efforts.
We are looking for a Bioinformatics Scientist to analyze proprietary human genetic variation data and associated medical information to uncover gene-disease links and new targets, new indications for existing drug targets, and new ways to stratify disease-bearing populations. Implement and develop analysis pipeline using cutting-edge algorithms and statistically sound methodologies.
This Scientist will:
- Collaborate with scientists from Human Genetics, Pre-clinical, and Clinical departments to design experiments linking variation to medical information. Communicate results with scientists, refine analysis based on feedback, and plan/prioritize follow-up experiments. Prepare clear, concise and easy-to-understand presentations and documentation for collaborators, senior management and regulatory agencies.
- Have responsibility for variant calling and filtering as part of DNA analysis pipelines and subsequent association analyses.
- Analyze proprietary and public genetics data to support identification of new drug targets.
- Analyze proprietary and public genetics data to suggest new indications for existing drug therapeutics.
- Analyze proprietary and public genetics data to support Clinical studies
- Analyze proprietary and public genetics data to suggest new disease stratification strategies.
- Participate in team effort of organizing and integrating proprietary and public genetics data to enable data sharing and visualization for bench scientists.
- Contribute to team effort of developing genetics analytical strategies and establishing data analysis best practices.
This position requires a PhD in biology, bioinformatics, biostatistics, or computational biology with strong publication record and 5-10 years experience.
This experience must include:
- Expertise in analysis of human next-generation sequencing data and knowledge of best practices.
- Expertise in assessment of genetic variation and deleterious effects.
- Experience in analysis genetic sequencing data in the public domain.
- Familiarity with modeling (e.g., machine learning) and network building (e.g. gene regulation networks), as well as a keen interest and determination to be at the cutting-edge of algorithms and model building.
- Experience with relevant Sequencing Analysis tools; such as BWA, GATK, SAMtools or related.
- Familiarity with bioinformatics tools and software such as R, Linux, Perl, Python, Ruby, Java, Ruby on Rails, MatLab, SQL, and web development tools.
- Ability to work both independently and collaboratively with commitment to share data across the organization.
- Excellent communication and presentation skills required.
- Experience with Cloud-based analytical tools and parallel processing is strongly preferred, but not required
This is an opportunity to join our select team that is already leading the way in the Pharmaceutical/Biotech industry. Apply today and learn more about Regeneron’s unwavering commitment to combining good science & good business.
To all recruitment agencies:
Regeneron is using the agency management company, Candex - www.candex.com. Please, no phone calls or emails to any employee of Regeneron about this opening. All resumes submitted by search firms/employment agencies to any employee at Regeneron via-email, the internet or in any form and/or method without a valid written search firm agreement in place for this position will be deemed the sole property of Regeneron. No fee will be paid in the event the candidate is hired by Regeneron as a result of the referral or through other means.
Regeneron is an equal opportunity employer and is an affirmative action employer.
To apply for this position, please CLICK HERE